ALS/FTD Genes Converge on Endolysosomal System, Stoking TDP-43 Pathology
TANK-binding kinase 1 gets wrapped up in poly-GA aggregates translated from C9ORF72. TDP-43 aggregation ensues.
6538 RESULTS
Sort By:
TANK-binding kinase 1 gets wrapped up in poly-GA aggregates translated from C9ORF72. TDP-43 aggregation ensues.
USP11 spurs tau acetylation and aggregation. In women, one copy escapes X-inactivation.
ADNI4 will run from 2022 to 2027 and recruit 500 new participants, at least half of whom will be from underrepresented racial and ethnic groups.
Data from two large international familial cohorts predict disease onset, helping researchers select the best participants for secondary prevention trials.
Middle-aged people who strode 8,000+ steps a day were less likely to have a range of conditions, including diabetes and hypertension.
Blocking glycolysis triggers microglia to crank up lipid metabolism, boosting ATP production and improving phagocytosis. In Alzheimer’s disease, the opposite happens.
18F-Cholestify binds to the enzyme that generates 24-hydroxycholesterol, which readily clears the blood-brain barrier.
With lecanemab likely to garner FDA approval next year, Alzheimerologists are pondering how clinical practice, and their science, will be transformed.
Analysis of 168 metabolites in one blood sample foretold 10-year risk of developing common disorders.
VAMP2 helps distinguish pure dementia with Lewy bodies from DLB with Alzheimer’s. A synaptic protein panel distinguished FTLD-TDP-43 from FTLD-tau.
Slow clearance of an MRI tracer offers evidence of inefficient glymph transport in the brain.
Staying lucid as a centenarian may depend on the immune system you inherit.
Sharp at 100+? Thank You, Genes. Thank You, Immune System. In Hydrocephalus, Does Slow Drainage Cause Dementia? Differential Diagnosis: Can Synaptic Proteins Get It Done? Kuopio Alzheimer Symposium (9th) and Nordic Memory Clinic Conference (3rd)
The agency, under pressure from advocacy groups, considers uncertainty about efficacy to be acceptable.
The blood protein tempers APOE4 risk in E2 carriers yet accentuates it in E4 homozygote people.
No filters selected